May 30, 2001
For Immediate Publication

NEWPORT BEACH, CALIFORNIA - Ci-Tec, Ltd., a subsidiary of MBG Technologies, Inc., today announced that its newest proprietary non-coherent light source, the LumaCare® LC-122, will be shown in the company's booth at the upcoming International Photodynamic Association's 8th World Congress of Photodynamic Medicine, which will be held in Vancouver, British Columbia, Canada on June 5 - 9, 2001. More information about the IPA Congress is available at www.derm.ubc.ca/pdt2001/.

Based on MBG's patented non-coherent light source technology for Photodynamic Therapy (PDT), the LC-122 is a compact, lightweight and portable system that is more affordable to implement than lasers, as well as safer and easier to use. The LumaCare LC-122 addresses the two key issues for the PDT industry that are critical to market acceptance: 1) the ability to produce the light needed for any and all PDT drug protocols and 2) an affordable, universal price acceptable for the entire medical industry, from drug companies to physicians to medical insurers. Under $10,000 in moderate volumes, the LC-122 is designed for high volume manufacturing.

According to Mark Gart, Ci-Tec's President and Chief Executive Officer, "Traditional light sources used in PDT have been lasers which are expensive due to complex optics and controls, as well as mandated laser safety requirements for a sterile environment. In addition, most lasers are able to produce only a narrow range of light frequencies. Therefore, they're limited in their use for PDT studies as several frequencies may be required for various types of PDT treatments, such as fluorescent diagnostic and actual treatments."

Mr. Gart continued, "LumaCare achieves clinical functionality in a single system that offers an affordable method of PDT treatment. Our systems require minimal training of medical staff, little maintenance and no re-calibrations. One LC-122 system can be used in multiple treatment rooms, thereby increasing the number of patients that can be treated and not limiting the types of PDT protocols that can be used."

The main unit of the LC-122 provides the full spectrum of visible light in a single non-coherent light source, can generate any visible light frequency (400mm-800mm), and activates all currently approved PDT pharmaceuticals and multiple protocols, for total treatment flexibility. The system's interchangeable probes filter and focus the light to a specific frequency and beam pattern. Each probe is protocol-specific and easily connected with a single interlocking connection. Unlike laser-based systems, the LC-122 permits PDT drugs and protocols to be changed in a matter of seconds, along with frequency and power requirements, and do so very cost-effectively.

"The LumaCare LC-122 is suitable for all medical disciplines including dental, dermatology, oncology, ophthalmology and veterinary," said Mr. Gart. "Because it's a complete solution, it's affordable for our pharmaceutical partners to bundle the LC-122 with new PDT protocol introductions. For physicians and patients, it's a safe and effective PDT drug activation system. We believe our simple and cost-effective approach will appeal to medical insurers and facilitate medical reimbursement."

MBG Technologies recently received a U.S. Patent for Ci-Tec's LumaCare Lamp technology. PDT is one of the most promising new fields of medicine to emerge for the non-invasive treatment of tissue diseases and disorders. Photosensitive drugs are applied on the skin and penetrate through to the diseased tissue, or they are injected into the blood stream from which the affected area absorbs the drug. Once the drugs are in place, they may be selectively activated via specific light frequencies. The LumaCare lamp activates the drugs by irradiating the tissues with a fixed frequency light source unique to each drug and disease. The drugs absorb the targeted light, which then stimulate them to destroy only the diseased tissues that have absorbed the drugs.

For additional information or to place an order, please visit our web site at www.LumaCare.com, or contact our London Sales office at Phone: +44 (0207) 724 7675 or e-mail: info@LumaCare.com